ArticleEuropean radiology experimental2026
Mesenteric and antimesenteric border subregionalization using MR enterography: advancing fibrosis evaluation in Crohn disease.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectiveAssessment of intestinal fibrosis is an unmet need for patients with Crohn's disease (CD), but spatial heterogeneity of fibrosis may affect accuracy. We developed and validated a novel strategy based on subregionalization into mesenteric and antimesenteric borders on magnetic resonance enterography (MRE). MATERIALS AND
methodsWe included 184 CD patients across two surgical and one follow-up cohorts. For 12 patients who underwent MRE and surgery (Cohort 1), MRE coregistration with ileal specimens was achieved for 88 sections using three-dimensional-printing and creeping fat information. Optimal multivariable MRE models for mesenteric border, antimesenteric border, and whole-circle regions were constructed referencing histological fibrosis and validated in another 21 patients (Cohort 2). The impact of this strategy on the prediction of disease progression was assessed in a retrospective follow-up cohort of 151 patients (Cohort 3).
resultsHistological fibrosis scores were higher in mesenteric than antimesenteric regions in both surgical cohorts (p < 0.001). MRE models showed the highest diagnostic accuracy for fibrosis in the mesenteric border (area under the receiver operating characteristic curve [AUROC] 0.91), followed by the antimesenteric border (AUROC 0.84), and the whole-circle (AUROC 0.77) regions in Surgical Cohort 1. In surgical Cohort 2, MRE also showed higher efficacy in mesenteric (AUROC 0.87) than antimesenteric border (AUROC 0.77). In Cohort 3, baseline fibrosis measurements in the mesenteric border (hazard ratio [HR] 9.25) had the greatest predictive value on disease progression versus other regions (HR 0.28‒2.09).
conclusionIntestinal fibrosis demonstrates spatial heterogeneity. Subregionalization into mesenteric and antimesenteric borders improves MRE diagnostic power and may aid in predicting CD progression. RELEVANCE STATEMENT: Mesenteric and antimesenteric border subregionalization on MRE advances fibrosis evaluation in CD by addressing the spatial heterogeneity of fibrosis, enabling tailored therapeutic strategies and identifying high-risk patients with disease progression. KEY POINTS: Spatial heterogeneity of intestinal fibrosis in CD limits the diagnostic accuracy of conventional whole-region MRE analysis. Fibrosis is more severe in the mesenteric than the antimesenteric border, with subregional MRE analysis outperforming whole-circle analysis in fibrosis detection. Baseline mesenteric border fibrosis severity most strongly predicts CD progression, necessitating subregionalization for outcome prediction and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.